Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Non-Current Deffered Revenue (2016 - 2017)

Crescent Biopharma (CBIO) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $801058.0 as the latest value for Q3 2017.

  • For Q3 2017, Non-Current Deffered Revenue fell 4.8% year-over-year to $801058.0; the TTM value through Sep 2017 reached $801058.0, down 4.8%, while the annual FY2016 figure was $753579.0, 209.29% up from the prior year.
  • Non-Current Deffered Revenue hit $801058.0 in Q3 2017 for Crescent Biopharma, up from $742584.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $841426.0 in Q3 2016 and bottomed at $9709.0 in Q3 2014.
  • Average Non-Current Deffered Revenue over 5 years is $385423.2, with a median of $243647.0 recorded in 2015.
  • Year-over-year, Non-Current Deffered Revenue decreased 27.5% in 2015 and then skyrocketed 2739.56% in 2016.
  • Crescent Biopharma's Non-Current Deffered Revenue stood at $96756.0 in 2013, then increased by 0.26% to $97012.0 in 2014, then soared by 151.15% to $243647.0 in 2015, then surged by 209.29% to $753579.0 in 2016, then increased by 6.3% to $801058.0 in 2017.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $801058.0, $742584.0, and $824653.0 for Q3 2017, Q2 2017, and Q1 2017 respectively.